RecruitingNot a traditional drug phaseobservationalRules rewrite

Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to…

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess the change in disease activity of risankizumab treatment in adult participants with moderate to severe UC in real-world clinical practice.

Official registry: https://clinicaltrials.gov/study/NCT06764706 · AbbVie · enrollment listed as 200

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 200 people at 57 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

A Prospective, Real-World Study EvalUating the EffectiveNess and Safety of RISankizumab in PatiEnts With Ulcerative Colitis (SUNRISE-UC)

Primary outcome (registry wording): Percentage of Participants Achieving Symptomatic Remission Responder Per Partial Adapted Mayo Score

Who it is for (from inclusion criteria)

Ages 18 Years to any
Participants with an endoscopically confirmed diagnosis of moderate to severe ulcerative colitis
Participants initiating risankizumab at the investigator's discretion as part of their routine clinical care; the decision to administer risankizumab must be made prior to and independent of documentation for the study and according to the approved local label

Who the registry excludes

Participants previously exposed risankizumab
Participants who are currently participating in treatment research (not including noninterventional studies, post-marketing watch-and-measure (no experimental treatment required) study (PMOS), or registry participation)

Public study contact (from the registry)

Medical Information Germany

49 611 1720 1520

medinfo.germany@abbvie.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

57 listed

Universitaetsklinikum Heidelberg /ID# 275906 — Heidelberg, Baden-Wurttemberg, Germany (recruiting)
Klinikum Ernst Von Bergmann /ID# 278268 — Potsdam, Brandenburg, Germany (recruiting)
Private Practice Dr. Katharina Pfeifer /ID# 286373 — Wriezen, Brandenburg, Germany (recruiting)
Private Practice - Dr. Kempelmann /ID# 275726 — Tostedt, Free and Hanseatic City of Hamburg, Germany (recruiting)
Gastroenterologische Schwerpunktpraxis - Hannover /ID# 276701 — Hanover, Lower Saxony, Germany (recruiting)
Praxis fuer Gastroenterologie - Schwerin /ID# 275946 — Schwerin, Mecklenburg-Vorpommern, Germany (recruiting)
Medizinisches Versorgungszentrum Ahaus /ID# 280966 — Ahaus, North Rhine-Westphalia, Germany (recruiting)
Gastropraxis Bochum /ID# 281375 — Bochum, North Rhine-Westphalia, Germany (recruiting)
Katholisches Klinikum Bochum gGmbH /ID# 279486 — Bochum, North Rhine-Westphalia, Germany (recruiting)
Evangelisches Krankenhaus Kalk /ID# 276414 — Cologne, North Rhine-Westphalia, Germany (recruiting)
Universitaetsklinikum Duesseldorf /ID# 280409 — Düsseldorf, North Rhine-Westphalia, Germany (recruiting)
Dres. Kamp & Partner /ID# 275904 — Minden, North Rhine-Westphalia, Germany (recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseLeuven, Vlaams-Brabant

Not a traditional drug phase: Sample collection for IBS

Aim: More insight in pathogenesis of IBS and IBD. Samples are collected in context of an European research project.

NCT02421705 · Official ClinicalTrials.gov record · KU Leuven

RecruitingNot a traditional drug phaseHouston, Texas

Not a traditional drug phase: testing Ustekinumab for Crohn Disease

This study wants to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

NCT04372108 · Official ClinicalTrials.gov record · Janssen Scientific Affairs, LLC

RecruitingNot a traditional drug phaseToronto, Ontario

The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Dise…

Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn's disease (CD), constitute a group of debilitating chronic diseases that profoundly impact patient quality of life and incurs large costs in terms of treatment and lost productivity. Incidence of IBD is rising worldwide, and there is a pressing clinical need for development of new therapies.

NCT06006039 · Official ClinicalTrials.gov record · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

FAQ about this NCT record

Is NCT06764706 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06764706?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06764706?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary